Log In

 

Company Name : LFB S.A.

Friday, December 22, 2017 11:30AM IST (6:00AM GMT)

(BW)(LFB-S.A.)

Denis DELVAL is Appointed CEO of LFB SA


Les Ulis, France

On December 20th, a decree from the President of France was published in Le Journal Officiel* appointing Denis DELVAL CEO of LFB S.A. This decree follows the General Meeting of LFB SA and the meeting of its Board of Directors, which both took place on December 4th, 2017.

 

This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171221005345/en/

 

Denis DELVAL, CEO of LFB S.A. (Photo: Business Wire)

Denis DELVAL, CEO of LFB S.A. (Photo: Business Wire)

Denis DELVAL is also appointed, CEO of LFB BIOMEDICAMENTS and President of LFB BIOTECHNOLOGIES as of December 4th, following Christian BÉCHON and Denis SOUBEYRAN’s departures.

 

A graduate of ESSEC and INSEAD business schools with a PhD in Pharmacy, Denis DELVAL has a deep understanding of the pharmaceutical industry. He has held important marketing, sales and strategic positions in France, Europe and worldwide and has managed international partnerships within various pharmaceutical groups (Bayer, Fournier Pharma, ALK). In 2006, he was appointed General Manager of ALK France. In 2012, he also became Senior Vice President of the Danish pharmaceutical company specialized in allergy immunotherapy treatments. Denis DELVAL lectures at ESSEC business school and has also been Chairman of Lecrip.org, a healthcare think tank.

 

“I am proud to be appointed as CEO of LFB Group and to work for this company operating in a strategic sector. LFB produces therapeutics that are essential for the lives of thousands of patients, particularly in the rare disease field. I am fully aware of the challenges ahead and look forward to unleashing energies to make this pharmaceutical company successful in France and internationally.”

 

* The Official Journal of the French Republic.

 

About LFB Group
LFB is a biopharmaceutical group that develops, manufactures, and markets medicinal products derived from living matter for the treatment of serious and often rare diseases in several major therapeutic fields, including Hemostasis, Immunology and Intensive Care. LFB is the leading manufacturer of plasma-derived medicinal products in France and 7th worldwide, and is also among the leading European companies for the development of new-generation medicinal products or treatments based on biotechnologies. Through its constant research efforts, the LFB group implements a growth strategy to expand its activities on international markets. Today, LFB currently markets its products in almost 60 countries around the world with a global turnover of €518.9 million in 2016. LFB group employs more than 2300 people worldwide.
www.groupe-lfb.com

 

 

 

 

 

 
MULTIMEDIA AVAILABLE :
http://www.businesswire.com/news/home/20171221005345/en/


Click here for Media Contact Details
CONTACTS :

LFB SA
Sandrine Charrières, Tel : +33-(0)1-6982-7280
Executive VP Corporate Communications
charrieres@lfb.fr


More News from LFB S.A.

06/01/2017 9:01PM

LFB S.A. Announced Today the Acceptance by U.S. Food and Drug Administration of the Filed Biologic License Application for Coagulation Factor VIIa Recombinant, (eptacog beta activated)

LFB S.A., announced that its Biologic License Application (BLA), requesting marketing approval of Coagulation Factor VIIa (Recombinant) as a treatment for congenital hemophilia A or B in adolescent and adult congenital ...

Similar News

24/04/2018 7:34PM

People Matter: William Sim, President of Heilind Asia Pacific

William Sim never forgot the advice he received from one of his former CEOs, and it’s something he has carried into all of his leadership roles.   When William Sim entered the world of electronics, he ...

No Image

24/04/2018 7:23PM

New Analyses from Pivotal Phase III Trials of Oral Ozanimod in Relapsing Multiple Sclerosis To Be Presented at the 2018 American Academy of Neurology Annual Meeting

Reductions in annualized relapse rates shown in pivotal trials with ozanimod were consistent in subgroups including baseline disability, gadolinium-enhanced lesion status and prior exposure to disease-modifying ...